title: Recommendations on the use of everolimus in lung transplantation.
abstract: The antiproliferative effect of everolimus provides a therapeutic option in the immunosuppression therapy of lung transplantation, by reducing both the risk of acute rejection and the process of progressive fibrosis that determines chronic graft rejection. However, few data on the use of everolimus in lung transplantation have been published to date, and the specific indications of the drug, along with the most adequate time for its introduction or dosing, have not been defined yet. The aim of this article is to propose recommendations for the use of everolimus in lung transplant recipients, including indications, dosing schedules and the use of concomitant immunosuppression. This consensus document has been developed by experts of all the Spanish lung transplant groups from the review of the existing literature and the clinical experience.
authors.affiliation: University Hospital, Doce de Octubre, Madrid, Spain. alic1575@separ.es
authors.forename: A
authors.initials: A
authors.lastname: de Pablo
authors.forename: F
authors.initials: F
authors.lastname: Santos
authors.forename: A
authors.initials: A
authors.lastname: Solé
authors.forename: J M
authors.initials: JM
authors.lastname: Borro
authors.forename: J M
authors.initials: JM
authors.lastname: Cifrian
authors.forename: R
authors.initials: R
authors.lastname: Laporta
authors.forename: V
authors.initials: V
authors.lastname: Monforte
authors.forename: A
authors.initials: A
authors.lastname: Román
authors.forename: M
authors.initials: M
authors.lastname: de la Torre
authors.forename: P
authors.initials: P
authors.lastname: Ussetti
authors.forename: F
authors.initials: F
authors.lastname: Zurbano
mesh_terms: D000970:Antineoplastic Agents; D000068338:Everolimus; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016040:Lung Transplantation; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus